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See Article, pages 794–799In 1981, Lebrec et al. proposed for the ﬁrst time the use of
b-blockers in the prophylaxis of variceal bleeding in patients with
cirrhosis [1,2]. This advanced knowledge has been a milestone for
research inHepatology in the last century, and it has inspiredanera
of lively research about the pathophysiology of the portal system
and the potential clinical use of medical treatments able to reduce
portal pressure. In particular, several randomized trials and cost-
effectiveness analyses have conclusively demonstrated that non
selective b-blockers are the ﬁrst choice medications for primary
prophylaxis against variceal bleeding in patients with varices
[3,4]. More recently, randomized, controlled trials [5–7] have
reported a lower rate of variceal bleeding among patients treated
with endoscopic banding – a procedure usually reserved for
acutely bleeding varices or secondary prophylaxis – than among
patients treated with b-blockers, although no effect on mortality
has been noted [3,4]. However, these studies are limited by their
short follow-up and small size. Until future studies address these
issues, gastroenterologists will continue to choose non selective
b-blockers for primary prophylaxis in most patients and reserve
endoscopic interventions for primary prophylaxis in patients
who cannot tolerate b-blockers, or in those with large varices
who live far from medical care facilities [4]. On the other hand,
combination therapywithnon selectiveb-blockersandendoscopic
banding should be preferred in the prevention of variceal re-bleed-
ing or secondary prophylaxis [3]. Themechanismof action of these
medications is complexandvaries according to thedose. Lowdoses
of non-selective b-blockers cause unopposed splanchnic vasocon-
striction, leading to reduced portal blood ﬂow and, consequently,
decreasedportal hypertension. As thedose is increased, portal ﬂow
is further reduced by the negative effect of these medications on
cardiac output. Furthermore, there is also evidence that thesemed-
ications decrease the development of portosystemic collaterals, an
important precursor to the formation of varices [4]. Over the past
twenty years, the impairment of the systemic and splanchnic
hemodynamics in patients with cirrhosis has been observed as
being progressive, so that somehallmarks of this impairment, such
as splanchnic arterial vasodilation, the degree of portal pressure
and the degree of reduction of the effective circulating volume,
and the consequent degree of activation of the systemic endoge-
nous vasoconstrictors systems become more and more evidentJournal of Hepatology 20
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become evident that the secondary progressive increase in cardiac
output becomes inadequate to support the progressive fall in
peripheral vascular resistance, thereby contributing to a further
impairment of the effective circulating volume in the more
advanced stages of liver disease [10]. On clinical grounds, these
hemodynamic changes result in the deﬁnition of distinct clinical
stages of liver disease with a markedly different prognosis. In par-
ticular, the onset of ascites and its progression toward refractory
ascites and/or hepatorenal syndrome has proved to have a deep
negative impact on survival [11]. Therefore, the questions to be
addressed were the following: (a) how does the hemodynamic
effect of b-blockers change in the more advanced stages of cirrho-
sis? And, accordingly, (b) how do b-blockers affect the survival of
patients with more advanced cirrhosis, for example in those with
refractory ascites, which is deﬁned as a lack of response to high
doses of diuretics, or as the recurrent development of side effects
when even lower doses of diuretics are used?
Prior to the ﬁrst recent study from the Lebrec’s research team
[12], there was no sufﬁcient data to answer these questions. Only
a retrospective analysis based on the presence of ascites at ran-
domisation in a multicenter Italian Clinical trial showed that sur-
vival was shorter in ascitic patients given propranolol than in
those receiving a placebo [13]. Sersté et al. showed that consider-
ing patients with cirrhosis and refractory ascites, the median sur-
vival was 5.0 months in those treated with propranolol and
20.0 months in patients not treated with propranolol [12]. As a
consequence, the authors suggested for the ﬁrst time that
b-blockers should be contraindicated in patients with cirrhosis
and refractory ascites. This conclusion has provoked a strong
interest and a lively debate in the scientiﬁc community, as high-
lighted by several letters of comments. Some authors have high-
lighted limitations on the observational character of the study
[14–16], on the inclusion criteria, or on the description of the
patients included [14]. Other authors have objected to what con-
cerns the statistical analysis or the dose of propranolol [17].
Nonetheless, few authors openly discussed the ﬁnal conclusion
of the paper of Sersté et al. even if they recognized that an impor-
tant question had been raised about the safety of b-blockers in
patients with cirrhosis and refractory ascites [16].
Based on these results, Lebrec and his research team have now
deepened their investigations on the use of b-blockers in patients
with cirrhosis and refractory ascites, evaluating the effects of these11 vol. 55 j 743–744
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drugs on the paracentesis-induce circulatory dysfunction (PICD).
PICD is a further impairment of systemic and splanchnic hemody-
namics and a further decrease in effective arterial blood volume,
which is triggered by large volume paracentesis and is detected
by an increase in plasma renin activity or concentration (PRC) of
at least 50% above baseline one week after paracentesis [18].
Patients who develop post-paracentesis circulatory dysfunction
(PICD) are at risk of developing hyponatremia and renal impair-
ment and have a low probability of survival [18]. In order to eval-
uate the effects of b-blockers in the development of PICD, Sersté
et al. performed a self control cross-over study [19]. Ten patients
with cirrhosis and refractory ascites treated with b-blockers were
selected. Heart rate, arterial pressure, and plasma renin concentra-
tions (PRC) were collected before, immediately after, and 1 week
after large-volume paracentesis associatedwith intravenous albu-
min administration. b-blockers were progressively discontinued
after complete endoscopic eradication of varices. The clinical and
biological evaluation was then repeated. When patients were
given b-blockers, the prevalence of PICD was 80%. After the with-
drawal of b-blockers, the prevalence of PICD dropped to 10%.
Therefore, the authors concluded that the use of b-blockers may
be associated with a high risk of PICD in patients with cirrhosis
and refractory ascites [19]. The results of this study lend further
support to the conclusion of the ﬁrst study of Sersté et al. as the
development of a PICD could have contributed to the increased
mortality among patients with cirrhosis and refractory ascites
who had received propranolol. In addition, they raise some fasci-
nating pathophysiological questions; ﬁrst of all, can propranolol
reduce the cardiac output in patients with cirrhosis and refractory
ascites to such an extent to further impair the effective circulating
volume? The study of Sersté et al. in the current issue of the Journal
of Hepatology has some important limitations. First, it is an explor-
atory pilot study performed in few patients with cirrhosis and
refractory ascites. A randomized controlled trial or a parallel con-
trol design in a large sample of patients would probably be more
appropriate to evaluate the effects of a speciﬁcmedication. In addi-
tion, the lack of assessment of cardiac dysfunction and the lack of a
short follow up to evaluate the clinical consequences of PICD rep-
resent other important limitations of the study. Nevertheless,
these limitations are clearly indicated in the discussion where
the authors stated with great intellectual honesty that ‘‘their
results should be extrapolated with caution and further studies
are needed to conﬁrm these ﬁndings’’. As a consequence, I think
that if this manuscript stimulates the design of some randomized
controlled clinical trials on the issue of safety of b-blockers in
patientswith cirrhosis and refractory ascites, the authorswill have
hit their target. Therefore, my last and most important comment
on this study of Sersté et al. will cover its ethical aspects rather than
its scientiﬁc andmethodological ones. I feel that great credit is due
to Dr. D. Lebrec and all the othermembers of his research group for
having reviewed, with critical goals, the use of b-blockers in
patients with cirrhosis, which, do not forget, represents their most
relevant clinical achievement in the last 30 years. This way of con-
ducting scientiﬁc research is a rare and precious gift because it is
the only way to search for the truth. I want to cite a sentence from
the speech of Pope John Paul II at the Pontiﬁcal Academy of
Sciences, November 13th, 2000 [20]. ‘‘Truth, freedom, and respon-
sibility are connected in the scientist. In fact, in embarking upon
the path of his research, he understands that hemust do it not only
with the impartiality required by the objectivity of themethod, but
also with the intellectual honesty, responsibility, and I would say744 Journal of Hepatology 201with a sort of reverence which is suitable to the human spirit in
his approach to the truth.’’
I ﬁnd that in the progressive critical review of their main dis-
covery, Dr. D. Lebrec and his research group reﬂect the tenor of
this deﬁnition.Conﬂict of interest
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